Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...

Sen. Bernie Sanders grilled the maker of Wegovy and Ozempic on why the drugs cost so much more in the U.S. than in European countries.

With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans ...

While Ozempic is not FDA-approved for weight loss, semaglutide, the active ingredient ... but it’s unlikely insurance will cover medication costs for this use. On the other hand, many insurance ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

Aiming to tackle the high risk of heart problems among older Americans with obesity, Medicare is contemplating an expansion ...

Online companies like Noom and Hims & Hers this year began selling compounded semaglutide ... are selling are roughly a fifth of the monthly cost of a drug like Ozempic. Drugmakers like Novo ...

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs ... work developing semaglutide, the active ...

Drug companies are under fire for the high cost of Ozempic and simlar meds. A doctor said patients who can't afford it may get riskier online versions.

Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...

which can cost more than $1,000 a month in the U.S. Semaglutide, a drug in the GLP-1 class that is marketed as Wegovy for weight loss and Ozempic for type 2 diabetes, has been shown to help ...